Clinical trials: Time
Short Bowel Syndrome, Parenteral Nutrition Associated Liver Disease
Study of NST-6179 in Healthy Subjects
A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.
- Trial name
- NCT05181085
- Testing
- NST 6179
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Healthy Subjects
Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects
Primary: To assess the effects of ascending repeated-doses of oral [p.o.] neramexane at therapeutic and supra-therapeutic steady-state doses on cardiac repolarisation (QT/QTc interval) in healthy male and female subjects.
- Trial name
- NCT00978614
- Testing
- Neramexane
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Neoplasms
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in…
- Trial name
- NCT04446351
- Testing
- GSK6097608, Dostarlimab, Cobolimab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Musculoskeletal Pain
Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain
The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.
- Trial name
- NCT04193631
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Pure Green
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT
The objective of the study is to determine whether patients with poor glycemic control can improve metabolic control using the real-time values of the Guardian® RT compared to conventional self-monitoring blood glucose…
- Trial name
- NCT00111228
- Testing
- Guardian RT, SMBG only
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 162 people
- Sponsor
- Medtronic MiniMed, Inc.
Atrial Arrhythmia
EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients
The purpose of this study is to evaluate the incidence and evolution over-time of co-morbidities in a general dual-chamber pacemaker population (n=2188 patients) through a 2 years follow-up.
- Trial name
- EMERALD (NCT01188356)
- Where
- 190 sites in United States, Australia and 10 more
- Volunteers
- 4,350 people
- Sponsor
- MicroPort CRM
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Drug-Drug Interaction Study Between Colchicine and Diltiazem ER
Colchicine is a substrate for both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Extended-release diltiazem (diltiazem ER) is a potent inhibitor of both CYP3A4 and P-gp.
- Trial name
- NCT00983372
- Testing
- Colchicine, Diltiazem ER
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Membranous Nephropathy - PLA2R Induced, Kidney Diseases-except Membranous Nephropathy
Clinical Trial of PLA2R-IgG4 Detection Kit (Time-resolved Fluorescence Immunoassay)
The goal of this observational clinical trial is to compare assessment reagents with clinical diagnostic criteria in patients with membranous nephropathy.
- Trial name
- NCT05861869
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Zhejiang Biostar Biotechnology Co.
Pulmonary Disease, Chronic Obstructive
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study is to demonstrate that, when added to tiotropium (TIO), fluticasone propionate/salmeterol combination (FSC) DISKUS 250/50 significantly increases exercise endurance time (EET) in the endurance shuttle…
- Trial name
- ESWT (NCT01124422)
- Testing
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Where
- 27 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI)
Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.
Complicated urinary tract infections (cUTIs) often lead to the overuse of empiric antibiotics, risking inappropriate treatment and contributing to antimicrobial resistance.
- Conditions
- Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
- Trial name
- PCR (NCT06996301)
- Testing
- Treatment guided by the PCR results, Treatment guided by the C&S results
- Where
- 6 sites in United States
- Volunteers
- 773 people
- Sponsor
- Doc Lab Inc
Vitrectomy
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)
- Trial name
- MIVI-10 (NCT01159665)
- Testing
- ocriplasmin
- Where
- Belgium
- Volunteers
- 38 people
- Sponsor
- ThromboGenics
Healthy Volunteer
At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations
This will be a single centre, open label, randomised, two-way crossover study in healthy volunteers under semi-fed conditions. Two formulations of paracetamol, are being tested in this study to establish at what time point a…
- Trial name
- NCT01551836
- Testing
- Paracetamol formulation 1, Paracetamol formulation 2
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Treated With Insulin
A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections
The purpose of this study is to collect CGM, A1c and Quality of Life data in subjects with Type 2 diabetes before and after transitioning from Multiple Daily Injections to Basal plus Bolus with Afrezza® inhaled insulin.
- Trial name
- NCT04125082
- Testing
- Afrezza Inhalant Product
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Diabetes and Glandular Disease Clinic
Ulcerative Colitis
Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis
The primary objective of the study was to compare the percentage of subjects in remission after 8 weeks of treatment with SPD476, 2.4 g/day once daily vs placebo and SPD476 4.8 g/day once daily versus placebo
- Trial name
- NCT00548574
- Testing
- SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine, Mesalazine
- Where
- Belgium
- Volunteers
- 343 people
- Sponsor
- Shire
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00769886
- Testing
- Ketotifen/naphazoline, Ketotifen, Naphazoline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Bausch & Lomb Incorporated
Alert Fatigue, Health Personnel
Study to Evaluate Efficacy of EnXtra on Accuracy & Reaction Time, Perceived Alertness & Digital Fatigue for Video Gamers
In the present study, Sponsor aim to evaluate the effects of EnXtra® as to improve Accuracy \& Reaction Time, Perceived Alertness \& Digital Fatigue for Video Gamers.
- Trial name
- NCT05586880
- Testing
- Experimental: EnXtra 300 mg/ capsule, Microcrystalline cellulose (MCC) 300mg
- Where
- 2 sites in India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Sepsis, Abdominal Sepsis
Personalised Real-time Interoperable Sepsis Monitoring (PRISM)
The goal of this prospective observational study is to develop and utilize an Artificial Intelligence (AI) model for the prediction of postoperative sepsis in patients undergoing abdominal surgery.
- Conditions
- Sepsis, Abdominal Sepsis, Infections, Clinical Deterioration
- Trial name
- PRISM (NCT06238180)
- Testing
- PRISM Tool
- Where
- Greece
- Sponsor
- Aisthesis Medical P.C.
Lymphedema of Upper Arm
Auto-Adjustable MOBIDERM® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase
This study aims to assess Auto-Adjustable MOBIDERM® Autofit Armsleeve effect on upper limb volume excess after 3 months of maintenance phase treatment in patients with secondary upper limb lymphedema following breast cancer.
- Trial name
- LYMphoNIGHT (NCT04203069)
- Testing
- Control group : Day-time compression sleeve, Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit
- Where
- 8 sites in France, Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Thuasne